According to Asia News' report on May 21st, Thailand's Minister of Public Health, Somsak Thepsutin, announced on Monday (20th) that marijuana will be reclassified as a Schedule 5 controlled substance within this year.
A survey conducted by the National Institute of Development Administration (NIDA Poll) in Thailand showed that 60.38% of respondents "completely agree" with the reclassification of marijuana as a drug, 15.27% "somewhat agree," 14.5% "completely disagree," 8.93% "strongly disagree," and 0.92% did not comment. Additionally, 46.95% of respondents believe that the government should not compensate individuals affected by the reclassification, 35.03% believe compensation should be given to marijuana growers and businesses, and 10.08% believe compensation should only be given to growers. The survey included 1310 individuals aged 15 and older nationwide and was conducted on May 14th and 15th.
According to a NIDA poll, 68.93% of respondents have never used marijuana, while 31.07% have used it at some point.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
